Ruxolitinib: A Novel Molecule in the Management of Dermatological Disorders

    February 2026 in “ Indian Journal of Skin Allergy ”
    Shreya Datta, Sushil Kumar Singh, Disha Chakraborty, Abhishek De, Sandipan Dhar
    Ruxolitinib (RUX) cream 1.5% is a topical JAK 1 and 2 inhibitor approved for atopic dermatitis and non-segmental vitiligo, showing significant efficacy in reducing inflammation and pruritus with minimal systemic absorption. In phase III trials, RUX improved global assessment and severity scores in atopic dermatitis and achieved superior repigmentation rates in vitiligo. Common side effects include application site reactions. Emerging evidence suggests potential off-label use for conditions like alopecia areata, though further research is needed. RUX cream offers a promising targeted therapy with localized efficacy and minimal systemic risk.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    4 / 4 results

      community What else is good. Besides the big 3.

      in Chat  35 upvotes 1 year ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community I had claude create a protocol only using fda approved drugs.

      in Research/Science  2 upvotes 1 month ago
      A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

      community Ruxolitinib - Start of a case study

      in Research/Science  10 upvotes 1 year ago
      The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

      community No hair, don't care! [24/F] :)

       60 upvotes 10 years ago
      A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.

    Similar Research

    6 / 481 results